Based on the information available, there is no definitive evidence to suggest that Cosentyx (secukinumab) impacts the effectiveness of COVID-19 vaccines. Secukinumab is a biologic medication used to treat various inflammatory diseases, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

A study published in the Journal of Allergy and Clinical Immunology: In Practice investigated the impact of biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) on the immune response to mRNA COVID-19 vaccines in patients with rheumatic diseases [2]. The study did not specifically mention Cosentyx or secukinumab, but it did include other biologics with similar mechanisms of action. The results showed that most patients developed an immune response to the vaccine, although the response was generally weaker in those on biologics or targeted synthetic DMARDs compared to those not on these medications [2].

It is important to note that the study did not directly assess the impact of Cosentyx on COVID-19 vaccine effectiveness [2]. Therefore, further research is needed to determine the specific effects of Cosentyx on the immune response to COVID-19 vaccines.

In summary, there is currently no evidence to suggest that Cosentyx has a significant impact on COVID-19 vaccine effectiveness. However, patients taking biologics like Cosentyx may have a slightly reduced response to COVID-19 vaccines, and it is recommended that they continue to follow public health guidelines to protect themselves from infection [2].

Sources:

1. Cosentyx (secukinumab) [Internet]. DrugPatentWatch.com. [cited 2022 Mar 22]. Available from: https://www.drugpatentwatch.com/drugs/cosentyx
2. Furer V, Ben-Chetrit E, Shitrit D, et al. Humoral and cellular immune responses to SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases: a prospective observational study. J Allergy Clin Immunol Pract. 2022;10(2):552-561.e5. doi:10.1016/j.jaip.2021.12.016